{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:44:42Z","timestamp":1793371482349,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T00:00:00Z","timestamp":1688256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>In October 2020 and March 2021, the U.S. Food and Drug Administration (FDA) classified lamotrigine as a class IB antiarrhythmic, announcing an increased risk of heart rhythm problems. We sought to investigate the nature of the arrhythmia signal with lamotrigine use compared to anticonvulsants with sodium\u2010blocking and non\u2013sodium\u2010blocking mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective pharmacovigilance case\u2013non\u2010case study used disproportionality analysis to detect signals of adverse reaction of interest reported with lamotrigine to the FDA Adverse Event Reporting System (FAERS) between 1998 and 2022. Our regression model adjusted for interacting concomitant medications. Sensitivity analyses included stratifying by indication and publication date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 2917 cases of heart rhythm problems with anticonvulsants were analyzed (1557 female [58.4%] and 1109 male [41.6%]). The mean age \u00b1 standard deviation (SD) was 43\u2009\u00b1\u200919, the groups did not differ significantly by age. Forty cases (7.91%) in the epileptic indication included more than one concomitant medication that influences cardiac conduction. The disproportionality signal for cardiac arrest did not differ for lamotrigine compared with other anticonvulsants, adjusted reporting odds ratio (adj.ROR, .88; 95% CI, .59\u20131.29) in the epileptic indication. A significantly lower reporting risk for bradyarrhythmia was identified with lamotrigine users in the epileptic population, (adj.ROR, .45; 95% confidence interval [CI], .29\u2013.68). The psychiatric indication demonstrated a sixfold reporting risk for cardiac arrest compared to the epileptic indication. Concomitant medications that affect cardiac conduction, as well as reports on overdose and suicide attempts, were significant variables in psychiatric patients (ROR, 2.45; 95% CI, 2.21\u20132.71) and (ROR, 1.44; 95% CI, 1.34\u20131.55), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Our results do not support a significant difference in the reporting risk for cardiac arrest, syncope, tachyarrhythmia, and bradyarrhythmia with lamotrigine in the epileptic indication. Signals of cardiac arrest in lamotrigine could be explained by confounding factors in the psychiatric indication, such as greater concomitant use of medications with cardiac adverse events, and greater reports on overdose and suicide attempts. We recommend that patients with polypharmacy undergo clinical and electrocardiographic monitoring. We illustrate the importance of examining signals for separate indications.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.17696","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:20:18Z","timestamp":1687652418000},"page":"2322-2329","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-9523","authenticated-orcid":false,"given":"Mohammed","family":"Aboukaoud","sequence":"first","affiliation":[{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University  Tel\u2010Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Wilf\u2010Yarkoni","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University  Tel\u2010Aviv Israel"},{"name":"Department of Neurology Rabin Medical Center  Tel\u2010Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Maor","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University  Tel\u2010Aviv Israel"},{"name":"The Olga &amp; Lev Leviev Heart Center, Sheba, Medical Center  Ramat Gan Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,2]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"FDA label information. Accessed September 2022. Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1310e776\u201065c8\u2010413d\u2010aab5\u201081a8c15719c5"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200427030\u201000002"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476\u20105381.2011.01415.x"},{"key":"e_1_2_10_5_1","unstructured":"Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease. Accessed September 2022. Available from:https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/studies\u2010show\u2010increased\u2010risk\u2010heart\u2010rhythm\u2010problems\u2010seizure\u2010and\u2010mental\u2010health\u2010medicine\u2010lamotrigine"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535759721996344"},{"key":"e_1_2_10_7_1","unstructured":"EMA label information. Accessed November 2023. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/lamictal"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200164"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","unstructured":"CatterallWA Perez\u2010ReyesE SnutchTP StriessnigJ.Voltage\u2010gated calcium channels (CaV) in GtoPdb v.2021.3. IUPHAR\/BPS Guide to Pharmacology CITE.2021https:\/\/doi.org\/10.2218\/gtopdb\/F80\/2021.3","DOI":"10.2218\/gtopdb\/F80\/2021.3"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15313"},{"key":"e_1_2_10_11_1","unstructured":"FAERS database. Accessed September 2022. Available from:https:\/\/www.fda.gov\/drugs\/questions\u2010and\u2010answers\u2010fdas\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\/fda\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\u2010public\u2010dashboard"},{"key":"e_1_2_10_12_1","unstructured":"Medical dictionary for regulatory activities. Accessed September 2022. Available from:https:\/\/www.meddra.org\/"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"e_1_2_10_14_1","unstructured":"CredibleMeds. Accessed September 2022. Available from:https:\/\/crediblemeds.org\/healthcare\u2010providers."},{"key":"e_1_2_10_15_1","unstructured":"FDA label information. Accessed September 2022. Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9e79b42c\u201038a3\u20104b2c\u2010a196\u2010a5a1948250e2"},{"key":"e_1_2_10_16_1","unstructured":"Vigibase WHO Database. Accessed October 2022. Available from:https:\/\/who\u2010umc.org\/vigibase\/"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122674"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1351"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246\u2010200010001\u201000008"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1081\/clt\u2010120014645"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13311"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17339"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.643916"},{"key":"e_1_2_10_24_1","unstructured":"American Epilepsy Society Clinical Guidelines. Accessed May 2023. Available from:https:\/\/www.aesnet.org\/clinical\u2010care\/clinical\u2010guidance\/guideline\u2010prolonged\u2010seizures."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020477"},{"key":"e_1_2_10_26_1","unstructured":"FDA label information. Accessed September 2022. Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3dfb6da1\u2010f66a\u20104618\u20109f74\u2010d2d6c16c0b58"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.17696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T19:54:24Z","timestamp":1700682864000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.17696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,2]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/epi.17696"],"URL":"https:\/\/doi.org\/10.1111\/epi.17696","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,2]]},"assertion":[{"value":"2023-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}